Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CART-19 in Elderly Relapsed/Refractory B-ALL
NCT02799550Phase 1Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Oct 2015
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic CART-19 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by 307 Hospital of the People's Liberation Army. Primary endpoint: Occurrence of study related adverse events at 1 year. Status: unknown.
02
Drugs
allogeneic CART-19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02799550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799550.